National Bank of Canada FI Sells 64,340 Shares of BioNTech SE (NASDAQ:BNTX)

National Bank of Canada FI decreased its stake in shares of BioNTech SE (NASDAQ:BNTX) by 98.9% in the 2nd quarter, Holdings Channel reports. The fund owned 710 shares of the company’s stock after selling 64,340 shares during the quarter. National Bank of Canada FI’s holdings in BioNTech were worth $56,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BNTX. Dynamic Technology Lab Private Ltd lifted its stake in BioNTech by 2.5% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after acquiring an additional 116 shares in the last quarter. Covestor Ltd lifted its position in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. GAMMA Investing LLC boosted its holdings in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the last quarter. Arlington Capital Management Inc. grew its position in BioNTech by 10.0% in the first quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock valued at $203,000 after purchasing an additional 200 shares in the last quarter. Finally, Midwest Professional Planners LTD. increased its stake in BioNTech by 7.2% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after buying an additional 212 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. HC Wainwright restated a “buy” rating and issued a $113.00 price target on shares of BioNTech in a research note on Tuesday, August 27th. JPMorgan Chase & Co. dropped their price objective on BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a research note on Thursday, August 15th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Jefferies Financial Group boosted their target price on shares of BioNTech from $90.00 to $96.00 and gave the stock a “hold” rating in a report on Friday. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech presently has an average rating of “Hold” and a consensus price target of $108.00.

BioNTech Price Performance

NASDAQ:BNTX opened at $123.40 on Friday. The company has a market cap of $29.34 billion, a P/E ratio of 246.80 and a beta of 0.23. The firm’s fifty day moving average price is $87.28 and its two-hundred day moving average price is $89.67. BioNTech SE has a one year low of $76.53 and a one year high of $125.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The company had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s quarterly revenue was down 23.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.86) EPS. Equities analysts expect that BioNTech SE will post -2.8 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.